Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 96 points (-0.6%) at 16,467 as of Friday, Aug. 1, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 828 issues advancing vs. 2,201 declining with 119 unchanged. The Drugs industry currently sits down 1.7% versus the S&P 500, which is down 0.6%. On the negative front, top decliners within the industry include Novo Nordisk A/S ( NVO), down 2.6%, Biogen Idec ( BIIB), down 2.2%, Amgen ( AMGN), down 1.8%, Alexion Pharmaceuticals ( ALXN), down 1.6% and GlaxoSmithKline ( GSK), down 1.4%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Valeant Pharmaceuticals International is down $1.02 (-0.9%) to $116.37 on heavy volume. Thus far, 3.0 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $116.10-$120.60 after having opened the day at $118.67 as compared to the previous trading day's close of $117.39. Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $42.2 billion and is part of the health care sector. Shares are down 0.0% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity. Get the full Valeant Pharmaceuticals International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.